Latest News

23

August 2017

iX Biopharma Ltd. has reported results for the fourth financial quarter ended 30 June 2017 (unaudited) and commenced a multi-dose Phase 2 efficacy study with Wafermine (KET010) in the USA...

Read On

15

May 2017

iX Biopharma Ltd. has incorporated a new wholly owned subsidiary, Entity Health Pte Ltd (“Entity”), to promote and market its new line of products...

Read On

Our Sublingual Technology

Sublingual wafer administration offers the convenience of use over oral delivery, circumventing the drug breakdown in liver or gastrointestinal tract. The technology also provides rapid absorption, achieving maximum desirable therapeutic effect in a non-invasive manner.

Read On

Contact us

iX Biopharma Ltd

1 Kim Seng Promenade
#14-01 Great World City East Tower
Singapore 237994
T: +65 6235 2270
F: +65 6235 2170
E: info@ixbiopharma.com